Stock screener

ALKS

Conviction 82HealthcareScan · Mon, Aug 10, 2026
ALKS$49.42+0.50%
ResistanceSupportVol 14Insider sell
63 bars
Vol MA14 1.9M
May 11May 28Jun 16Jul 6Jul 23Aug 10
Alkermes plc.PHARMACEUTICAL PREPARATIONSwww.alkermes.com ↗
Price49.42
Change+0.50%
Gap-0.24%
Rel volume1.10×
Avg volume1.78M
Avg $ vol90.04M
SMA 2050.88
SMA 5049.12
SMA 20036.04
Price vs 50+0.60%
Price vs 200+37.11%
MA stackbullish
50/200 cross—
Supertrendup · 48.16
RSI (14)47
MACD hist-0.49
MACD cross—
Stoch %K / %D28 / 21
ADX (14)27
+DI / −DI14 / 20
RSI divergence—
MACD divergence—
ATR %+3.73%
ADR %3.54%
52w high55.22
52w low26.52
From 52w high-10.51%
Above 52w low+86.33%
New 52w highNo
SqueezeOff
Bollinger width12.76%
%B0.27
Donchian pos28.24%
Donchian high53.88
Donchian low47.66
AVWAP (52w high)51.20
vs AVWAP high-3.49%
AVWAP (52w low)35.07
vs AVWAP low+40.91%
OBV trendDown
Chaikin MF (20)-0.07
Today vs 20d1.10×
Avg vol (14d)1.9M
Avg vol (20d)1.78M
Avg $ vol (20d)90.04M
Market cap8.29B
RS 3m (vs SPY)+33.20%
RS 6m (vs SPY)+32.44%
RS line new highNo
Trend template8/8
Technical rank67.4
1 week-0.23%
1 month-4.86%
3 months+41.23%
6 months+41.55%
1 year+85.81%
YTD+74.86%
P/E34.30
P/B4.58
P/S5.62
P/FCF17.26
EPS1.43
Div yield—
ROE13.36%
ROA5.50%
Debt/Eq0.83
Current2.30
EV/EBITDA33.02
Gross margin—
Net margin16.37%
Rev growth-5.25%
EPS growth-34.16%
Price target58.25
Target upside17.88%
Analyst ratingBuy
Institutional123.10%
Ent. value9.28B
Revenue496.01M
Net income501K
Gross profit—
Free cash flow480.33M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out166.68M
Employees2.05K
ListedTue, Jul 16, 1991
Free float162.41M
Float %98.4%
Short interest15.02M
Days to cover9.1d
Short volume51.9%
Squeeze score53 / 100
Next earnings—
EPS forecast—
Last EPS vs est$0.00 vs −$0.04
Last surprise+100.0% beat
Setup gradeA
Conviction82 / 100
Pattern quality—
Tech rank67.4 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance55.47
Support47.94
Days since event—
Candle confirm—
News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ALKS

All disclosures →
No recent disclosed trades by Congress in ALKS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ALKS · 4 buys · 6 sells

InsiderSideShares
Jackson Blair Curtis
President & CEO, Alkermes plc · Employee Stock Option (Right to Buy) · 2026-08-05
Grant124.31K
Jackson Blair Curtis
President & CEO, Alkermes plc · Employee Stock Option (Right to Buy) · 2026-08-05
Grant93.23K
Gaffin David Joseph
EVP, CLO, Alkermes, Inc. · Ordinary Shares · 2026-07-06
Sell2.03K
Wright Christopher I
Director · Ordinary Shares · 2026-06-12
Sell2K
Gaffin David Joseph
EVP, CLO, Alkermes, Inc. · Ordinary Shares · 2026-06-04
Sell2.03K
Hopkinson Craig C.
EVP R&D, Chief Medical Officer · Employee Stock Option (Right to Buy) · 2026-06-01
Exercise5K
Hopkinson Craig C.
EVP R&D, Chief Medical Officer · Ordinary Shares · 2026-06-01
Sell9K
Hopkinson Craig C.
EVP R&D, Chief Medical Officer · Ordinary Shares · 2026-06-01
Exercise5K
Parisi Samuel Joseph
VP, Finance (Interim PAO) · Ordinary Shares · 2026-05-29
Sell16.22K
Parisi Samuel Joseph
VP, Finance (Interim PAO) · Ordinary Shares · 2026-05-29
Exercise12.82K

SEC filings

EDGAR filings in ALKS · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.